VALUE-Dx (Value of diagnostics to combat antimicrobial resistance by optimizing antibiotic use) is an Innovative Medicines Initiative (IMI) project which aims to combat antimicrobial resistance (AMR) and improve patient outcomes.  VALUE-Dx is a unique multidisciplinary consortium, with participation of clinicians, microbiologists, health economists, social scientists, and industry, that should help to build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

For further information, please visit:

Please view the VALUE-Dx presentation’s video:

Courses and events


Fight to antimicrobial resistance: the role of new diagnostics, ERS Congress, Barcelona 2022

Emerging data for the management of respiratory tract infections, ERS virtual congress 2021

Community-acquired respiratory tract infections: where do we stand in 2021, ECCMID 2021

Antibiotic resistance: the way forward, ERS virtual congress 2020

VALUE-Dx course, Madrid, 2 to 3 April 2019

Symposium, ERS congress, Madrid 2019